Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS (REFALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03505021
Recruitment Status : Recruiting
First Posted : April 20, 2018
Last Update Posted : May 14, 2019
Sponsor:
Information provided by (Responsible Party):
Orion Corporation, Orion Pharma

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : August 30, 2020
  Estimated Study Completion Date : October 30, 2020